Citigroup Inc Paratek Pharmaceuticals, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$1.67 - $2.51 $1,050 - $1,578	-629 Reduced 99.68%	2 $0
Q3 2022 Nov 10, 2022	SELL	$1.96 - $2.93 $1,336 - $1,998	-682 Reduced 51.94%	631 $2,000
Q2 2022 Aug 10, 2022	SELL	$1.73 - $3.09 $2,930 - $5,234	-1,694 Reduced 56.34%	1,313 $3,000
Q1 2022 May 12, 2022	SELL	$2.94 - $4.77 $34,271 - $55,603	-11,657 Reduced 79.49%	3,007 $9,000
Q4 2021 Feb 10, 2022	BUY	$4.07 - $5.3 $24,725 - $32,197	6,075 Added 70.73%	14,664 $66,000
Q3 2021 Nov 10, 2021	BUY	$4.7 - $7.24 $40,368 - $62,184	8,589 New	8,589 $42,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.